中生制药(01177.HK)气管药贴剂首仿获批上市 打破进口药物垄断

阿斯达克财经
Feb 07, 2025

中生制药(01177.HK) 公布,集团开发的“妥洛特罗贴剂”(商标名为“德瑞妥”)已获得国家药监局的上市批准,用于缓解支气管哮喘、急性支气管炎、慢性支气管炎、肺气肿等气道阻塞性疾病所致的呼吸困难等症状。这是首个获批上市的国产气道阻塞性疾病外用贴剂。妥洛特罗贴剂的适应人群广泛,半岁及以上儿童即可使用。相较于口服、吸入制剂,妥洛特罗贴剂用药简单方便,解决了儿童给药困难的问题,减少了因操作不当而导致的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10